Skip to main content
All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for NOVOCURE INC. · Commercial stage oncology dedicated to advancement of TTF therapy to treat solid tumors.

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Income
$60,000
What the client paid this registrant for the period.
Client based in
New Hampshire

Official filing document

 Lobbyists on this filing 4
  • JEANNE HAGGERTY
    Previously held: Legislative Correspondent Senator Chuck Grassley and Senate Aging Committee (shared staff), Legislative Aide Senate Finance Committee, Health Policy Coordinator Health Subcommittee Energy and Commerce, Professional Staff Member
  • ROBERT BUTORA
    Previously held: Health Policy Advisor, Senator Bill Cassidy; Senior Health Policy Advisor, Representative Leonard Lance, Health Legislative Assistant, Representative Michael Burgess
  • DANIEL ZIEGLER
    Previously held: Executive Director, Republican Study Committee; Legislative Director for Rep Doug Lamborn, Policy Director; Speaker Mike Johnson
  • JOSHUA DAVID FENDRICK
    Previously held: Staff Assistant, Legislative Correspondent, and Legislative Aide, Sen. Gary C. Peters; Economic Policy Adviser, Rep. Josh Gottheimer; Economic Policy Adviser, Sen. Gary C. Peters

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Medicare/Medicaid

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices.

Pharmacy

Breakthrough pathway bill (H.R. 5343, S. 1717), CMS reimbursement of medical devices generally, and FDA issues related to medical devices. CMS RAPID Proposed Rule.

 Bills named in this filing 2
  • H.R. 5343
    Ensuring Patient Access to Critical Breakthrough Products Act
  • S. 1717
    Ensuring Patient Access to Critical Breakthrough Products Act of 2025
 Foreign interests disclosed 2

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • NOVOCURE GMBH
    Switzerland · 6340 Baar · owns 100% of the client · contributed $0
  • NOVOCURE LUXEMBOURG S.A.R.L. (OWNS 100% OF NOVOCURE GMBH)
    Luxembourg · L-1273, Luxemborg · owns 100% of the client · contributed $0

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem